ATE267591T1 - Optimierte tobramycin-formulierung zur aerosolbildung - Google Patents

Optimierte tobramycin-formulierung zur aerosolbildung

Info

Publication number
ATE267591T1
ATE267591T1 AT01116071T AT01116071T ATE267591T1 AT E267591 T1 ATE267591 T1 AT E267591T1 AT 01116071 T AT01116071 T AT 01116071T AT 01116071 T AT01116071 T AT 01116071T AT E267591 T1 ATE267591 T1 AT E267591T1
Authority
AT
Austria
Prior art keywords
formulation
optimized
aerosol formation
tobramycin formulation
tobramycin
Prior art date
Application number
AT01116071T
Other languages
English (en)
Inventor
Chiara Malvolti
Raffaella Garzia
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE267591(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of ATE267591T1 publication Critical patent/ATE267591T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01116071T 2001-07-02 2001-07-02 Optimierte tobramycin-formulierung zur aerosolbildung ATE267591T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01116071A EP1273292B1 (de) 2001-07-02 2001-07-02 Optimierte Tobramycin-Formulierung zur Aerosolbildung

Publications (1)

Publication Number Publication Date
ATE267591T1 true ATE267591T1 (de) 2004-06-15

Family

ID=8177921

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01116071T ATE267591T1 (de) 2001-07-02 2001-07-02 Optimierte tobramycin-formulierung zur aerosolbildung

Country Status (26)

Country Link
US (5) US6987094B2 (de)
EP (1) EP1273292B1 (de)
JP (1) JP4262086B2 (de)
KR (1) KR100910888B1 (de)
CN (1) CN1234346C (de)
AT (1) ATE267591T1 (de)
AU (1) AU2002319226B2 (de)
BG (1) BG66328B1 (de)
BR (1) BRPI0211320B8 (de)
CA (1) CA2452638C (de)
CZ (1) CZ299348B6 (de)
DE (1) DE60103527T2 (de)
DK (1) DK1273292T3 (de)
EA (1) EA006068B1 (de)
EE (1) EE05392B1 (de)
EG (1) EG24019A (de)
ES (1) ES2222294T3 (de)
HU (1) HU230807B1 (de)
PL (1) PL202598B1 (de)
PT (1) PT1273292E (de)
SI (1) SI1273292T1 (de)
SK (1) SK285806B6 (de)
TN (1) TNSN03149A1 (de)
TR (1) TR200401980T4 (de)
WO (1) WO2003004005A1 (de)
ZA (1) ZA200400026B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
DE60103527T2 (de) * 2001-07-02 2005-06-16 Chiesi Farmaceutici S.P.A. Optimierte Tobramycin-Formulierung zur Aerosolbildung
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
IL163843A0 (en) * 2002-03-01 2005-12-18 Chiesi Farma Spa Formoterol superfine formulation
CA2541849C (en) * 2003-10-15 2012-07-31 Pari Gmbh Liquid preparation containing tobramycin
US8442280B2 (en) * 2004-01-21 2013-05-14 Edda Technology, Inc. Method and system for intelligent qualitative and quantitative analysis of digital radiography softcopy reading
BRPI0509026A (pt) 2004-05-17 2007-09-18 Corus Pharma Inc formulação de aerossol, método para a prevenção e tratamento de infecção causada por bactéria do trato respiratório, e, solução
US8524735B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
WO2007041156A2 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
US20090246146A1 (en) * 2008-01-25 2009-10-01 Botond Banfi Halides in the treatment of pathogenic infection
US8629139B2 (en) * 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
CA2739897C (en) * 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
CA2752296C (en) * 2009-02-18 2018-09-11 Aradigm Corporation Ph-modulated formulations for pulmonary delivery
DK2473170T3 (da) 2009-09-04 2019-08-12 Horizon Orphan Llc Anvendelse af aerosoliseret levofloxacin til behandling af cystisk fibrose
EP2388008A1 (de) 2010-05-14 2011-11-23 Combino Pharm, S.L. Stabile, konservierungsmittelfreie, wässrige Formulierung zur Verabreichung durch Aerosolisierung enthaltend Tobramycin
US8598131B2 (en) * 2010-07-12 2013-12-03 Xellia Pharmaceuticals Aps Method for treatment of lung infections by administration of aminoglycosides by aerolisation
CN111388489A (zh) * 2010-09-13 2020-07-10 苏黎世大学 安普霉素在制备细菌感染性疾病治疗中的应用
ES2913095T3 (es) 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
PL2567691T3 (pl) 2011-09-12 2015-05-29 Meiji Seika Pharma Co Ltd Kompozycje wodne obejmujące arbekacynę
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN105534961B (zh) * 2015-12-30 2019-06-04 孙红娟 妥布霉素吸入溶液及其制备方法
CN105616345B (zh) * 2016-03-01 2018-08-21 上海方予健康医药科技有限公司 一种妥布霉素吸入组合物及其制备方法和用途
CA3046085A1 (en) * 2016-12-09 2018-06-14 Enbiotix, Inc. Aminoglycoside potentiation for treatment of pulmonary bacterial infection
CN108014099B (zh) * 2017-12-15 2019-03-01 武汉兴华智慧医药科技有限公司 一种吸入用妥布霉素溶液及其制备方法
GB2565941A (en) * 2018-11-27 2019-02-27 Norton Healthcare Ltd A process for preparing a formulation
CN113018443B (zh) * 2019-12-27 2022-09-13 海南斯达制药有限公司 治疗呼吸系统疾病的药物组合物及其制备方法
CN113952320B (zh) * 2021-09-18 2022-03-18 健康元药业集团股份有限公司 一种包含妥布霉素吸入溶液的药物组件及其用途

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
MX3864E (es) 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
US4185100A (en) 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US4584320A (en) 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
JPH06503066A (ja) 1990-12-19 1994-04-07 スミスクライン・ビーチャム・コーポレイション エアロゾル処方
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
ATE171630T1 (de) 1991-05-21 1998-10-15 Abbott Lab Aerosolinhalationsvorrichtung
SK24494A3 (en) 1991-08-29 1994-09-07 Christoph Klein Medicinal device for inhalation of dosed aerosols
IL103238A (en) 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
DK0617610T3 (da) 1991-12-18 1997-10-06 Minnesota Mining & Mfg Suspensionsaerosolformuleringer.
DE4230876A1 (de) 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
EP0673240B1 (de) 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilisierte medizinische aerosollösungen
SE9203743D0 (sv) 1992-12-11 1992-12-11 Astra Ab Efficient use
AU4066693A (en) 1992-12-23 1994-07-19 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
US5569450A (en) 1993-03-17 1996-10-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
AU679510B2 (en) 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing a diol-diacid derived dispersing aid
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
PT735884E (pt) 1993-12-20 2000-09-29 Minnesota Mining & Mfg Formulacoes de aerossol de flunisolida
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
WO1996019198A1 (en) 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5653961A (en) 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
JPH11509434A (ja) 1995-04-14 1999-08-24 グラクソ、ウェルカム、インコーポレーテッド サルメテロール用計量投与用吸入器
SI0820279T1 (en) 1995-04-14 2002-12-31 Smithkline Beecham Corporation Metered dose inhaler for albuterol
CA2218179A1 (en) 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for beclomethasone dipropionate
BR9604978A (pt) 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador com dose medida
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
EP0914143A1 (de) 1996-07-08 1999-05-12 Rhone-Poulenc Rorer Limited Medizinische aerosollösungsformulierungen mit cyclosporin-a
WO1998003533A1 (en) 1996-07-24 1998-01-29 Oligos Etc. And Oligos Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9620187D0 (en) 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
JP2001505171A (ja) 1996-12-04 2001-04-17 バイオグラン アイルランド（アール アンド ディ）リミテッド 製薬組成物及びその投与のための装置
DK1014943T3 (da) 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
BR7702049U (pt) 1997-09-05 1999-09-14 Chiesi Farma Spa Bico pulverizador para utilização em inalador oral para medicamentos aerossóis
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
US6045784A (en) 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
DE19847969A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
DK1283036T3 (da) 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
DE60103527T2 (de) * 2001-07-02 2005-06-16 Chiesi Farmaceutici S.P.A. Optimierte Tobramycin-Formulierung zur Aerosolbildung
EP1415647A1 (de) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
IL163843A0 (en) 2002-03-01 2005-12-18 Chiesi Farma Spa Formoterol superfine formulation
EP1340492A1 (de) 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung
US20050083693A1 (en) * 2003-10-21 2005-04-21 Timothy Garrett Flag illumination fixture

Also Published As

Publication number Publication date
SI1273292T1 (en) 2004-12-31
US20100098642A1 (en) 2010-04-22
EA200301305A1 (ru) 2004-06-24
DE60103527T2 (de) 2005-06-16
SK16432003A3 (sk) 2004-06-08
US20050163722A1 (en) 2005-07-28
CZ299348B6 (cs) 2008-06-25
EE05392B1 (et) 2011-04-15
HK1068784A1 (en) 2005-05-06
US7696178B2 (en) 2010-04-13
US6987094B2 (en) 2006-01-17
PL367139A1 (en) 2005-02-21
SK285806B6 (sk) 2007-08-02
TNSN03149A1 (en) 2005-12-23
AU2002319226B2 (en) 2006-07-06
WO2003004005A1 (en) 2003-01-16
DK1273292T3 (da) 2004-10-04
US20120184502A1 (en) 2012-07-19
CN1529589A (zh) 2004-09-15
EA006068B1 (ru) 2005-08-25
DE60103527D1 (de) 2004-07-01
US20110212912A1 (en) 2011-09-01
ES2222294T3 (es) 2005-02-01
US8168598B2 (en) 2012-05-01
EE200400050A (et) 2004-04-15
BG66328B1 (bg) 2013-06-28
CN1234346C (zh) 2006-01-04
PL202598B1 (pl) 2009-07-31
PT1273292E (pt) 2004-10-29
BRPI0211320B8 (pt) 2021-05-25
JP2004535454A (ja) 2004-11-25
EG24019A (en) 2008-03-25
BRPI0211320B1 (pt) 2015-08-18
TR200401980T4 (tr) 2004-09-21
HUP0400387A2 (hu) 2004-09-28
BG108475A (en) 2005-02-28
EP1273292B1 (de) 2004-05-26
US20040186064A1 (en) 2004-09-23
CA2452638A1 (en) 2003-01-16
JP4262086B2 (ja) 2009-05-13
HU230807B1 (hu) 2018-06-28
KR20040018403A (ko) 2004-03-03
KR100910888B1 (ko) 2009-08-05
US7939502B2 (en) 2011-05-10
CZ20033580A3 (cs) 2004-10-13
CA2452638C (en) 2010-10-05
BR0211320A (pt) 2004-09-28
EP1273292A1 (de) 2003-01-08
ZA200400026B (en) 2005-03-30

Similar Documents

Publication Publication Date Title
DE60103527D1 (de) Optimierte Tobramycin-Formulierung zur Aerosolbildung
PT1363600E (pt) Formulações líquidas para a prevenção e para o tratamento de doenças e distúrbios das mucosas
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
WO2002054868A3 (en) Pulmonary delivery of polyene antifungal agents
WO2001089496A3 (en) Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics
ES2136883T3 (es) Nueva formulacion mejorada de aminoglucosido para administracion en forma de aerosol.
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
WO2001064035A3 (en) Acidic antimicrobial compositions for treating food and food contact surfaces and methods of use thereof
EP1353647A4 (de) Inhalierbares aztreonam zur behandlung von und vorbeugung gegen bakterielle lungeninfektionen
DE69831816D1 (de) Bakterizide desinfizierende peressigsäure-zusammensetzung
DE60307860D1 (de) Aminocyclohexenchinoline und ihre azaisosterischen analoga mit antibakterieller wirkung
BR0212586B1 (pt) Composição na forma de uma solução aquosa, e, uso da mesma
PL1633376T3 (pl) Środki do profilaktyki i leczenia objawów przeziębienia i grypopodobnych zawierające chelatowany cynk
WO2003002064A3 (en) Fused pyrimidine dhfr inhibitors as antibacterials
WO2005110022A3 (en) Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
BRPI0411949A (pt) formulação inalável de lisinato de aztreonam para tratamento e prevenção de infecções pulmonares bacterianas
EA200300843A1 (ru) Вирулицидные композиции
BR0100228A (pt) Macrolìdeos com 13 e 14 elementos antibacterianos e procinéticos e seus intermediários
WO2006033713A3 (en) Methods for ciprofloxacin inhalation
ATE340182T1 (de) Sucroseoctasulphat silber saltz
MY129637A (en) Use of bismuth subgallate in inhibition of production of nitric oxide synthase.
BR0007491A (pt) Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções
RU2006142517A (ru) Стекло
RU2006143384A (ru) Стекло
TW200503734A (en) New use of soluble p-selectin and anthrax lethal toxin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1273292

Country of ref document: EP